HUTCHMED March 2026 slides: $1.4B cash fuels ATTC platform push

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump replaces Homeland Security chief Kristi Noem Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) HUTCHMED March 2026 slides: $1.4B cash fuels ATTC platform push By Company News Published 03/05/2026, 09:14 PM HUTCHMED March 2026 slides: $1.4B cash fuels ATTC platform push 0 HCM 1.50% Introduction & Market Context HUTCHMED (NASDAQ:HCM) presented its 2025 full-year results and strategic outlook on March 6, 2026, highlighting a strengthened financial position and advancement of its next-generation Antibody-Targeted Therapy Conjugate platform. Despite reporting solid commercial progress with its flagship oncology product FRUZAQLA®, the company’s stock dipped 1.39% in pre-market trading to $13.46, reflecting investor caution about near-term revenue dynamics. The biotechnology company showcased a cash position of $1.4 billion, up significantly from $836 million in 2024, primarily driven by proceeds from the partial divestiture of its Shanghai Hutchison Pharmaceuticals Limited equity stake. This financial flexibility positions HUTCHMED to accelerate development of its innovative ATTC platform while expanding its commercial footprint globally. Financial Performance Highlights HUTCHMED reported oncology/immunology revenue of $286 million for 2025, down from $363 million in 2024, as upfront payments and milestones declined to $71 million from $92 million year-over-year. However, the company achieved consolidated net income of $457 million compared to $38 million in 2024, largely attributable to a $416 million gain from the SHPL divestment. As illustrated in the company’s financial overview, research and development expenses decreased substantially to $148 million from $212 million, reflecting the transition from...